{"id":390940,"date":"2017-07-27T00:00:00","date_gmt":"2017-07-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0023-2017-biopharma-type-2-diabetes-treatment-algorithms-claims-data-analysis-us-2017\/"},"modified":"2026-05-07T11:25:42","modified_gmt":"2026-05-07T11:25:42","slug":"algomd0023-2017-biopharma-type-2-diabetes-treatment-algorithms-claims-data-analysis-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0023-2017-biopharma-type-2-diabetes-treatment-algorithms-claims-data-analysis-us-2017\/","title":{"rendered":"Type 2 Diabetes | Treatment Algorithms: Claims Data Analysis | US | 2017"},"content":{"rendered":"<p>Historically, biguanides and sulfonylureas were the most heavily prescribed\u00a0T2D\u00a0drug classes. However, the\u00a0DPP-IV\u00a0inhibitors have recently overtaken sulfonylureas to become the second-most heavily prescribed drug class. Numerous branded agents jostle for position as second-line treatment options, including the\u00a0DPP-IV\u00a0inhibitors, the\u00a0SGLT2inhibitors Jardiance, Invokana and Farxiga, the\u00a0GLP-1 receptor agonists Victoza and Trulicity, and the insulins. Adding to the complexity of the market dynamics, the biosimilar insulin Basaglar is also picking up significant patient share.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed type 2 diabetes patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed type 2 diabetes patients?<\/li>\n<li>What proportion of type 2 diabetes patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of type 2 diabetes patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with type 2 diabetes?<\/li>\n<\/ul>\n<p><strong>Key analysis provided:<\/strong>\u00a0<\/p>\n<ul>\n<li>Brand usage across longitudinal patient sample<\/li>\n<li>Newly diagnosed patient analysis<\/li>\n<li>Treatment initiation and progression<\/li>\n<li>Line of therapy analysis<\/li>\n<li>Combination therapy analysis<\/li>\n<li>Source of business for recently treated patients<\/li>\n<li>Persistency and compliance analysis<\/li>\n<li>Product-level patient flow charts<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong>\u00a0United States<\/p>\n<p><strong>Primary research:<\/strong>\u00a0 Longitudinal patient-level claims data analysis<\/p>\n","protected":false},"template":"","class_list":["post-390940","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390940\/revisions"}],"predecessor-version":[{"id":394064,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390940\/revisions\/394064"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}